Sorafenib (co-developed and co-marketed by Bayer and Onyx Pharmaceuticals as Nexavar), is a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma)...

  en.wikipedia.org

  medium.com

  xn---33-eddocrzmkdedshhfmddi3s.xn--p1ai

Все права охраняются. Summary Key words Lenvatinib, sorafenib, cost- effectiveness ratio (CER), budget impact analysis (BIA), pharmacoeconomics, thyroid ...

  elibrary.ru

  ro-journal.biomedcentral.com

Costs per QALY were 1 370 893,24 RUR and 1 379 841,33 RUR for everolimus and sorafenib consequently. ICER per QALY was 1 289 750 RUR. Profitability ...

  con-med.ru

The results obtained are resistant to an increase in the price of lenvatinib by 19.0 % and a decrease in the price of sorafenib by 52%. The average cost of therapy ...

  cyberleninka.ru

11 апр 2018 ... Сорафениб (Нексавар) - стандартный вариант системной терапии первого выбора для лиц с распространенной ГЦК или для лиц с ...

  www.infohep.org

  www.sorafenib24.com

Результаты. Замена препарата сорафениб на препарат ленватиниб при включении его ... of «cost-effectiveness», the drug lenvatinib dominates sorafenib.

  www.clinvest.ru

26 авг 2010 ... межуточной стадии [99], а в 2008 г. в нее включили сорафениб ...... plantation: a cost–benefit analysis while awaiting data on sorafenib ...

  www.easl.eu

Research objective: cost effectiveness evaluation of target therapy of medicinal products axitinib and sorafenib of mRCC patients that previously received ...

  elibrary.ru

In some patients, the sorafenib + CTA therapy has been replaced with lenvatinib. The only parameter analyzed in this model was the drug cost. In the BIA, the ...

  cyberleninka.ru

  www.slideserve.com

analysis, "budget impact" analysis, cost-effectiveness analysis, sensitivity analysis. Results. ... Results. The replacement of sorafenib with lenvatinib when .. .".

  www.clinvest.ru

  www.medexmd.com

29 авг 2018 ... Hepatocellular carcinoma after prior sorafenib treatment: incidence, healthcare utilisation and costs from German statutory health insurance ...

  socionet.ru

  www.pharmacychecker.com

Page generated - 0.0337259769 (8c6884a7359acaaacc90d5e994420076)